Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Summit Therapeutics ( (SMMT) ).
On January 22, 2025, Summit Therapeutics’ Board approved cash bonus awards for Dr. Mahkam Zanganeh, CEO, and Manmeet Soni, CFO, for their performance in the 2024 fiscal year, despite no bonuses being issued in 2023. The Board also increased their annual base salaries starting February 1, 2025. As of December 31, 2024, the company’s preliminary unaudited cash and investment balance was approximately $412 million, including the repayment of a $31.8 million related party loan, indicating a robust financial position.
More about Summit Therapeutics
Summit Therapeutics Inc. operates in the healthcare industry, focusing on developing and commercializing pharmaceutical products.
YTD Price Performance: 34.33%
Average Trading Volume: 2,244,012
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $18.18B
See more insights into SMMT stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “…Overlook a Lack of Earnings Power”: UBS Analysts Target Intel Stock (NASDAQ:INTC), Stock Gains
- “…Significantly Extend the Reach and Lethality of our Fleet”: Boeing Stock (NYSE:BA) Slips Despite Successful MQ-25A Test
- “Direct Result of Your Feedback….” Microsoft Stock (NASDAQ:MSFT) Slips as The Option to Skip Updates Emerges